Your fact-checks will appear here
Ivermectin neurotoxicity management and treatment
Laboratory and animal studies report that ivermectin and fenbendazole can kill cancer cells and boost certain chemotherapy effects, but there is no robust human evidence confirming safety or benefit w...
Ivermectin is FDA‑approved for a small set of parasitic indications in humans—oral tablets for certain internal worms and topical formulations for external parasites and some skin conditions—but it is...
Ivermectin can cause common, usually mild adverse effects such as headache, nausea, dizziness, diarrhea, and skin rash when given at approved human doses . Serious but rare harms include neurological ...
Ivermectin dosing is weight‑based, typically calculated in micrograms per kilogram and most often given as a single oral dose; common regimens for human parasitic infections fall between about 150 and...
Published human reports of ivermectin-associated neurotoxicity document either the drug’s detection in central nervous system tissue or clinical syndromes consistent with CNS penetration, but the revi...
Clinical trials and systematic reviews conducted during and after the COVID-19 pandemic provide limited information about ivermectin’s long-term safety in humans; most randomized trials report short f...
A large and disparate body of clinical research tested ivermectin for COVID‑19 using regimens ranging from single low antiparasitic doses (≈150–200 μg/kg) to multi‑day high‑dose courses (including stu...
Ivermectin tablets sold for human use are documented in official product labels and drug information sources as simple, uncoated, white to yellowish‑white tablets whose inactive ingredients are colloi...
High and repeated ivermectin doses explored for oncology have been tested in humans only in limited early-phase or dose‑escalation settings, showing that higher-than-approved regimens can be tolerated...
Patients who substitute ivermectin for proven cancer therapies have documented harms that fall into three categories: direct drug toxicity from unsupervised or high-dose use, dangerous drug–drug inter...
Human use of veterinary ivermectin since 2020 has been linked to a clear rise in poison‑center reports and clinically significant toxic effects, including hospitalizations, neurologic complications, a...
There are very few registered clinical trials testing ivermectin in cancer: the clearest active, publicly listed study is NCT05318469 (a phase I/II trial combining oral ivermectin with anti‑PD‑1 immun...
No completed human studies specifically reporting the safety or pharmacokinetics (PK) of high‑dose ivermectin in cancer patients have been published in the sources provided; the literature instead con...
Serious neurologic adverse events (encephalopathy, seizures, coma, persistent coma, ataxia) after ivermectin are uncommon but documented, and risk clusters around particular parasitic coinfections (no...
Documented human ivermectin neurotoxicity is uncommon but real: case series and pharmacovigilance reviews describe presentations ranging from confusion, ataxia and tremor to stupor and coma, sometimes...
Suspected ivermectin neurotoxicity is managed primarily with supportive care, close neurologic monitoring, and targeted interventions guided by toxicology consultation because no proven clinical antid...
Ivermectin produces neurotoxicity in humans when it accumulates in the central nervous system — a process normally blocked by P‑glycoprotein — and clinical reports link toxicity to doses well above st...
Human safety data for subcutaneous (SC) or intramuscular (IM) ivermectin intended for injection are extremely limited: a handful of case reports and small pharmacokinetic observations describe compass...
Documented human cases of ivermectin‑related neurotoxicity are rare but well described in the literature and fall into three broad patterns: mass‑treatment encephalopathies linked to parasitic coinfec...
Ivermectin is lipophilic, highly protein‑bound, and displays a human plasma half‑life around 18 hours with enterohepatic recycling and adipose accumulation that can prolong exposure . The drug’s acces...